Aptus Pharma Subscription
Last updated on 25-Sep-2025 17:13:10
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 352000 | 436000 | 1.24 |
| HNIs | 266000 | 7648000 | 28.75 |
| bHNI | 178000 | 5454000 | 30.64 |
| sHNI | 88000 | 2194000 | 24.93 |
| Individual | 620000 | 19552000 | 31.54 |
| Total | 1238000 | 27636000 | 22.32 |
Application-Wise Breakup  | |||
|---|---|---|---|
| Category | Reserved | Applied | Times |
| HNIs (10L+) | 30 | 326 | 10.87 |
| HNIs (3-10L) | 15 | 338 | 22.53 |
| Individual | 155 | 4888 | 31.54 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.1 | @8% ₹0.1 | @9% ₹0.1 | @10% ₹0.2 | @11% ₹0.2 | @12% ₹0.2 |
Aptus Pharma Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| bHNI | 8 | 16000 | 1120000 | 30 |
Aptus Pharma Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 528000 | 28.39% |
| QIB | 352000 | 18.92% |
| HNI | 266000 | 14.3% |
| INDIVIDUAL | 620000 | 33.33% |
| Market Maker | 94000 | 5.05% |
| Total | 1860000 | 100% |
Aptus Pharma About
IPO Details
| Total Issue Size | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Fresh Issue | 18,60,000 shares (aggregating up to ₹13.02 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 50,00,000 shares |
| Share Holding Post Issue | 68,60,000 shares |
| Reserved for Market Maker | 94,000 shares (aggregating up to ₹0.6580 Cr) |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. |
Key Performance Indicators (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 44.50% | 45.18% | 20.06% |
| ROCE | 45.66% | 21.70% | 12.77% |
| EPS (BASIC) | 6.37 | 5.32 | 1.3 |
| P/E Pre IPO | 11.29 | ||
| P/E Post IPO | 15.49 |
Company Financials (In ₹Crore)
| Period | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserves | 1.97 | 1.47 | 0.67 |
| Borrowing | 10.36 | 5.31 | 2.21 |
Peer Comparision (Valuation)
| Company | P/E (x) | CMP*(₹) | Face value (₹) |
|---|---|---|---|
| Aptus Pharma Limited | - | - | 10 |
| Zota health care limited | 382.12 | 1,207.50 | 10 |
| Sunrest Lifescience Limited | 10.56 | 49.2 | 10 |
| Lincoln Pharmaceuticals Limited | 13.53 | 556.1 | 10 |
Peer Comparision (Financial Performance)
| Company | NAV/Share (₹) | RoNW (%) | EPS (Basic) (₹) |
|---|---|---|---|
| Aptus Pharma Limited | 13.93 | 44.5 | 5.32 |
| Zota health care limited | 110.83 | 2.72 | 3.16 |
| Sunrest Lifescience Limited | 37.72 | 12.36 | 4.66 |
| Lincoln Pharmaceuticals Limited | 335.34 | 12.26 | 41.11 |
About Company
Business: A fully integrated pharmaceutical company that manufactures and distributes a wide portfolio of 194+ formulations across acute, chronic, and wellness therapies.
Key Divisions:
Aptus Pharma: Acute therapies (e.g., antibiotics, pain management)
Aptus CD Care: Chronic therapies (e.g., cardiology, antidiabetics)
Aptus Wellcare: Wellness & nutraceuticals
Aptus Global: Exports
Competitive Advantages:
Diverse Portfolio: Covers 11+ therapeutic areas.
Strong Distribution: Network of 125+ distributors and 54+ field personnel.
Cost-Effective: Strategic manufacturing partnerships in tax-benefit states (Gujarat, Uttarakhand, Himachal Pradesh).
Office Expansion: ₹1.63 Cr for new office space & furniture.
Fuel Growth: ₹8 Cr for working capital to fund daily operations and sales expansion.
Strategic Flexibility: Remaining funds for general corporate purposes.
Strength
Diversified Product Portfolio: The company offers over 194 pharmaceutical formulations across 11+ therapeutic segments, enabling it to cater to a wide range of patient and healthcare needs.
Strong Distribution Network: With a central warehouse in Ahmedabad and partnerships with logistics providers, the company ensures efficient, safe, and timely delivery across its target markets.
High-Quality Standards: The company follows WHO-GMP aligned protocols and rigorous testing at every production stage, ensuring product safety, consistency, and credibility.
Weakness
Regulatory Approvals: Failure to obtain, renew, or maintain necessary statutory and regulatory permits may disrupt operations and impact results.
Customer Concentration: Dependence on a few key customers makes revenue vulnerable if contracts are reduced or terminated.
Intellectual Property Risks: Inability to protect IP or allegations of infringement may result in loss of sales, liabilities, and adverse financial impact.
Aptus Pharma Lead Manager(s)
Aptus Pharma Address
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park,
Aslali, Ahmedabad, Daskroi,
Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/
Aptus Pharma Registrar
Aptus Pharma Reviewers
| Reviewer | Recommendation | File |
|---|